Correction: Fish oil: what the prescriber needs to know
Leslie G. Cleland, Michael J. James, Susanna Proudman · Arthritis Research & Therapy · 2006
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Arthritis Research & Therapy · BioMed Central · article · 2006
Abstract
It has been brought to our attention that there were a number of typographical errors in one section of our recent article [1] published in December 2005. All corrections apply to the section entitled, 'Biochemical rationale; Eicosanoids: cyclo-oxygenase pathway'. The second paragraph should read: The usual substrate for the COX isozymes is the n6 LC PUFA arachidonic acid (AA; C20:4n-6). Eicosapentaenoic acid (EPA; C20:5n-3), which is present in fish oil, differs from AA only by the presence of its n3 bond (Fig. 1).
The last sentence of the third paragraph should read: Thus, the net effect of fish oil is to reduce the production of proinflammatory and pro-thrombotic eicosanoids (PGE2 and TXA2, respectively) but not the vascular patency factor prostacyclin (PGI2; Fig. 2). Finally, the first 20-Carbon fatty acid homologue pictured in Figure 1 (C20:3 n-9) is eicosatrienoic acid, rather than oleic acid.
Open the resolved locator · 10.1186/ar1981
Metadata licence: OpenAlex metadata (CC0)